NECA in the Know

NECA AETC

A podcast for healthcare providers in the HIV field.

  1. Episode 184: What Is Direct-to-Inject?

    FEB 5

    Episode 184: What Is Direct-to-Inject?

    This week, Marianna sits down with Chris Bositis and Cara McAnaney from the National Clinician Consultation Center (NCCC) to talk all about lower-barrier substance use and HIV prevention and treatment. Tune in to learn how direct-to-inject ties into that and why it matters for you as an HIV care provider.  --  Resources:  Waters RC, Hoog J, Bell C, Toland P, Valley J, Hurtado L, Kallsen MA, Johnson T, Gerard A, Fockele CE, Klein JW. Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting. JAMA Netw Open. 2025 Aug 1;8(8):e2527016. doi: 10.1001/jamanetworkopen.2025.27016. PMID: 40815514; PMCID: PMC12357186. Rosenwohl-Mack S, Suen LW, Logan AA, Peterson D, Snyder HR. Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series. Subst Use Addctn J. 2025 Oct;46(4):1064-1069. doi: 10.1177/29767342251330412. Epub 2025 Apr 4. PMID: 40183345; PMCID: PMC12353995. D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702. PMID: 38976265; PMCID: PMC11231806.   Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941) -- Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. -- Check out our free online courses: www.necaaetc.org/rise-courses -- Download our HIV mobile apps: Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=US Apple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

    17 min
  2. Episode 179: What Happens When Treatment is Interrupted?

    11/13/2025

    Episode 179: What Happens When Treatment is Interrupted?

    This week, Marianna sits down with Carolyn Chu and Astha Kanani from the National Clinician Consultation Center (NCCC) to talk about treatment interruptions when it comes to HIV and Hepatitis C or HCV. Learn about why this can happen, the impact on treatment outcomes, and what you as an HIV care provider can do to prevent them.  --  Reach out to the NCCC at 844-ASK-NCCC or 844-275-6222.  Learn more at nccc.ucsf.edu.  Resources mentioned in this episode:  Dannenberg C, Matthews H, Hüfner A, et al.  Long-term real-world use of cabotegravir/rilpivirine: adherence and virological efficacy over a 44-month observation period.  Infect Dis Ther.  2025:14(8):1775-1797. De La Hoz A, Pooja A, Kancharla A, et al.  Characteristics and outcomes of direct-acting antiviral experienced patients with hepatitis C undergoing retreatment at an essential hospital in the United States.  Open Forum Infect Dis.  2024;11(12):ofae704. --  Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941) -- Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. -- Check out our free online courses: www.necaaetc.org/rise-courses -- Download our HIV mobile apps: Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=US Apple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

    17 min

Ratings & Reviews

5
out of 5
5 Ratings

About

A podcast for healthcare providers in the HIV field.